Stockreport

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF N-803 is being studied in three other HIV cure-related clinical trials CULVER CITY, Calif., March 05, 2024 BUSINESS WIRE )--ImmunityBio ( NASDAQ: IBRX ), a clinical-s [Read more]